Skip to main navigation Skip to search Skip to main content

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2603-2606
JournalEuropean Journal of Cancer
Volume47
Issue number17
DOIs
Publication statusPublished - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this